Palisade Bio Inc Dossier
Qualitative Analysis
Business overview
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company focused on developing next-generation, once-daily, oral phosphodiesterase-4 (PDE4) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. The company's lead clinical product candidate is PALI-2108, which is being developed as a targeted treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD). By utilizing a differentiated prodrug platform and precision pharmacology strategy, Palisade Bio aims to achieve localized bioactivation, enabling sustained target inhibition at the site of inflammation while minimizing systemic exposure and improving patient tolerability.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead program, PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, into Phase 2 clinical trials for Ulcerative Colitis and Crohn's Disease.
Expected impact: To establish clinical proof-of-concept, safety, and efficacy of a localized, gut-restricted oral PDE4 inhibitor, addressing major unmet needs in inflammatory bowel disease.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Palisade Bio with exclusive worldwide rights to develop, manufacture, and commercialize Giiant's proprietary targeted prodrug platform, including the lead asset PALI-2108 (formerly GT-2108) and GT-1908.
Terms: Palisade assumed all development, manufacturing, regulatory, and commercialization costs following the first IND/CTA approval. Palisade is obligated to pay certain milestone payments (in cash or stock at Palisade's election) and tiered royalty payments based on future net sales.
Aims to advance a precision medicine approach for ulcerative colitis therapy by leveraging Strand's bioinformatics and machine learning expertise to identify PDE4-related biomarkers and refine patient selection strategies.
Terms: Not explicitly disclosed.
Approved up to $500,000 in funding through the IBD Ventures program to support the continued clinical and mechanistic development of PALI-2108.
Terms: Strategic equity investment of up to $500,000.
Grants Newsoara exclusive co-development and commercialization rights for LB1148 in Greater China (excluding Taiwan).
Terms: Newsoara is responsible for fully funding Phase 3 development in China and is required to make milestone payments and tiered royalty payments on future annual net sales of LB1148 in the territory.